TheraRadar
Data updated: Mar 29, 2026

QVAR REDIHALER

BECLOMETHASONE DIPROPIONATE
Respiratory Approved 2017-08-03

QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm. ( 1 )...

Source: FDA Label • NORTON WATERFORD
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-08-03
Routes
INHALATION
Dosage Forms
AEROSOL, METERED

Companies

NORTON WATERFORD
Active Ingredient: BECLOMETHASONE DIPROPIONATE

QVAR REDIHALER Approval History

Loading approval history...

What QVAR REDIHALER Treats

1 indications

QVAR REDIHALER is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Asthma
Source: FDA Label

Drugs Similar to QVAR REDIHALER

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACCOLATE
ZAFIRLUKAST
1 shared
STRIDES PHARMA INTL
Shared indications:
Asthma
ADVAIR HFA
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
Asthma
AIRDUO RESPICLICK
FLUTICASONE PROPIONATE
1 shared
Teva
Shared indications:
Asthma
AIRSUPRA
ALBUTEROL SULFATE
1 shared
AstraZeneca
Shared indications:
Asthma
ALVESCO
CICLESONIDE
1 shared
COVIS
Shared indications:
Asthma
ARNUITY ELLIPTA
FLUTICASONE FUROATE
1 shared
GSK
Shared indications:
Asthma
ASMANEX HFA
MOMETASONE FUROATE
1 shared
Merck
Shared indications:
Asthma
BECLOMETHASONE DIPROPIONATE
BECLOMETHASONE DIPROPIONATE
1 shared
AMNEAL IRELAND LTD
Shared indications:
Asthma
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE ACETATE
1 shared
Hikma
Shared indications:
Asthma
BREO ELLIPTA
FLUTICASONE FUROATE
1 shared
GSK
Shared indications:
Asthma
BREYNA
BUDESONIDE
1 shared
Viatris
Shared indications:
Asthma
CELESTONE SOLUSPAN
BETAMETHASONE ACETATE
1 shared
Merck
Shared indications:
Asthma
CINQAIR
RESLIZUMAB
1 shared
Teva
Shared indications:
Asthma
DEPO-MEDROL
METHYLPREDNISOLONE ACETATE
1 shared
Pfizer
Shared indications:
Asthma
DEXAMETHASONE
DEXAMETHASONE
1 shared
ALVOGEN
Shared indications:
Asthma
DEXAMETHASONE INTENSOL
DEXAMETHASONE
1 shared
Hikma
Shared indications:
Asthma
DEXYCU KIT
DEXAMETHASONE
1 shared
EYEPOINT PHARMS
Shared indications:
Asthma
DULERA
FORMOTEROL FUMARATE
1 shared
Merck
Shared indications:
Asthma
DUPIXENT
DUPILUMAB
1 shared
Regeneron
Shared indications:
Asthma
EXDENSUR
DEPEMOKIMAB-ULAA
1 shared
GSK
Shared indications:
Asthma
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

QVAR REDIHALER FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use : Not indicated for the relief of acute bronchospasm.

QVAR REDIHALER Patents & Exclusivity

Latest Patent: Aug 2041

Patents (32 active)

US11583643 Expires Aug 19, 2041
US11957832 Expires May 5, 2041
US11559637 Expires Jul 21, 2039
US10792447 Expires Jan 25, 2039
US12296089 Expires Jan 26, 2038
US11793953 Expires Jan 26, 2038
US11395888 Expires Jan 26, 2038
US8931476 Expires Jul 17, 2031
+ 22 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA207921 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.